AIRNA raised $60 million in a Series A financing led by Forbion to advance RNA editing medicines and progress its AATD program into clinical trials.

Jul 31, 2024•over 1 year ago

Amount Raised

$60 Million

Round Type

series a

CambridgeBiotechnologyHealth Care

Investors

Nd CapitalArch Venture PartnersAlexandria Venture InvestmentsOno Venture InvestmentForbion

Description

AIRNA has successfully closed an oversubscribed $60 million Series A financing round, bringing total funding to $90 million. The funds will be utilized to advance their lead product candidate into clinical trials and further develop their pipeline.

Company Information

Company

Airna

Location

Cambridge, Massachusetts, United States

About

Airna, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.

Related People

5 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends